Efficacy of lopinavir-ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis.
Jiawen DengFangwen ZhouWenteng HouKiyan HeybatiSaif AliOswin ChangZachary SilverThanansayan DhivagaranHarikrishnaa Ba RamarajuChi Yi WongQi Kang ZuoElizabeth LapshinaMadeline MellettPublished in: Future virology (2022)
Aim: To evaluate the efficacy and safety of lopinavir-ritonavir (LPV/r) therapy in treating hospitalized COVID-19 patients. Materials & methods: Data from randomized and observational studies were included in meta-analyses. Primary outcomes were length of stay, time for SARS-CoV-2 test conversion, mortality, incidence of mechanical ventilation, time to body temperature normalization and incidence of adverse events. Results: Twenty-four studies (n = 10,718) were included. LPV/r demonstrated no significant benefit over the control groups in all efficacy outcomes. The use of LPV/r was associated with a significant increase in the odds of adverse events. Conclusion: Given the lack of efficacy and increased incidence of adverse events, the clinical use of LPV/r in hospitalized COVID-19 patients is not recommended.
Keyphrases
- sars cov
- mechanical ventilation
- risk factors
- meta analyses
- intensive care unit
- respiratory syndrome coronavirus
- systematic review
- acute respiratory distress syndrome
- randomized controlled trial
- electronic health record
- type diabetes
- double blind
- cardiovascular events
- stem cells
- adipose tissue
- bone marrow
- cell therapy
- placebo controlled
- combination therapy
- extracorporeal membrane oxygenation
- smoking cessation
- glycemic control